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INTRODUCTION 
Chronic	  Linphoci+c	  Leukemia	  is	  	  the	  most	  common	  
type	  of	  leukemia	  in	  adults.	  It	  represents	  25	  to	  35	  %	  
of	  all	  kinds	  of	  leukemia	  and	  aﬀects	  more	  men	  than	  
women.	   It	   is	   characterized	   by	   accumula+on	   of	  
mature	   B	   cells	   in	   blood,	   secondary	   lymphoid	  
organs	   and	   bone	   marrow.	   It	   is	   a	   very	  
heterogeneous	   disease,	   with	   a	   wide	   clinical	  
development,	   from	   nearly	   asymptoma+c	   with	  
slow	   progressive	   expansion,	   to	   very	   aggressive,	  
with	  quick	  evolu+on	  of	  the	  disease	  and	  an	  average	  
survival	  of	  one	  or	  two	  years.	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MATERIAL AND METHODS 
The	  aim	  of	  this	  work	  is	  to	  carry	  out	  a	  bibliographic	  review	  
about	  the	  most	  frequent	  gene+c	  abnormali+es	  in	  CLL	  and	  
their	  usefulness	  to	  perform	  and	  accurate	  prognosis,	  which	  
will	  help	  to	  classify	  pa+ents	  in	  diﬀerent	  risk	  subgroups	  so	  
they	  can	  be	  treated	  with	  the	  best	  therapy	  available.	  
It	  is	  a	  bibliographic	  review,	  so	  the	  informa+on	  and	  images	  
were	   mostly	   obtained	   from	   ar+cles,	   reviews,	   books	   and	  
doctoral	  thesis	  related	  with	  the	  topic,	  all	  of	  them	  cited	  in	  
the	  reference	  sec+on.	  	  
Prevalence Prognosis and average survival 
Related 
abnormalities  
7% Poor  32 months  Mutation of TP53  
18% Poor  79 months  Mutation of ATM 
16% Intermediate 114 months 
Gene dosage 
effect 




18% Intermediate 111 months None 
Chromosomal aberrations are detected in over 80% of patients analysed. In 
order to classify each patient depending on the alteration they carry, a 
hierarchical model, based in five categories, was designed, correlating the 
abnormalities detected by FISH and the course of the disease.  
GENETIC AND CITOGENETYCS OF CLL AND THEIR PROGNOSIS VALUE 
CYTOGENETIC ABERRATIONS AND THEIR 
PROGNOSTIC VALUE 
GENETIC MUTATIONS AND  
THEIR PROGNOSTIC VALUE 
Cytogenetic analysis is not enough to make a 
complete prognosis of the disease. The discovery of 
new alterations, such as recurrent gene mutations, 
are helping to identify new potential biomarkers 
with important prognostic value.  





























CLL	  is	  characterised	  by	  a	  set	  of	  well	  deﬁned	  recurrent	  altera+ons,	  which	  seem	  to	  have	  valuable	  clinical	  importance,	  in	  some	  cases	  bePer	  established	  than	  
others,	   like	  TP53	  altera+on,	  which	  at	  the	  present	   is	   the	  only	  molecular	  biomarker	  that	  changes	  therapeu+c	  approaches.	  That	  said,	  novel	   lesions	   in	  genes	  
such	   as	   SF3B1,	   NOTHC1	   or	   BIRC3	  might	   also	   have	   informa+ve	   prognosis	   value	   and	   help	   to	   make	   decisions	   about	   treatment	   in	   future.	   From	   a	   clinical	  
perspec+ve,	  aPempts	  to	  develop	  a	  new	  prognos+c	  model	  which	  would	  include	  both,	  chromosomal	  abnormali+es	  and	  gene	  muta+ons,	  have	  already	  begun,	  
but	  some	  discrepancies	  are	  emerging	  from	  diﬀerent	  studies,	  therefore,	  addi+onal	  examina+ons	  must	  be	  warranted	  before	  these	  schemes	  can	  be	  applicable.	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  main	  features	  are:	  	  
